Neuroscience 2001 Abstract
| Presentation Number: | 463.7 |
|---|---|
| Abstract Title: | Detection of Alzheimer's Amyloid by Magnetic Resonance Imaging. |
| Authors: |
Wisniewski, T. M.*1,2
; Wadghiri, Y. Z-.3
; Elliott, J. I.4,5
; Pappolla, M.7
; Duff, K.6
; Turnbull, D. H.3
; Sigurdsson, E. M.1,2
1Dept Neurology, New York Univ, Sch Med, New York, NY 2Dept Pathology, New York Univ, Sch Med, New York, NY 3Dept Radiology, New York Univ, Sch Med, New York, NY 4Molecular Biophysics, Yale University, New Haven, CT 5Biochemistry, Yale University, New Haven, CT 6Neuroscience, Nathan S. Kline Institute, Orangeburg, NY 7Pathology, University of South Alabama Medical Center, Mobile, AL |
| Primary Theme and Topics |
Neurological and Psychiatric Conditions - Neurodegenerative Disorders -- Alzheimers Disease: Other |
| Session: |
463. Neurodegenerative disorders: Alzheimer's disease--pathology and imaging Slide |
| Presentation Time: | Tuesday, November 13, 2001 9:30 AM-9:45 AM |
| Location: | Room 30C |
| Keywords: | Alzheimer's disease, transgenic mice, diagnosis, gadolinium |
A number of potential therapeutic approaches have been developed for the in vivo clearance of amyloid (Aβ) lesions, which characterize Alzheimer disease (AD). However, currently the definitive diagnosis of AD requires post-mortem examination. We present for the first time, a novel method for the detection of AD amyloid plaques by magnetic resonance micro-imaging(μMRI) using transgenic mouse models of AD. This method utilizes Aβ1-40 peptides which are labeled with either gadolinium (Gd) or monocrystalline iron oxide nanoparticles (MION). When either of these ligands are injected systemically with mannitol to transiently open the blood-brain barrier, we are able to image the majority of both early preamyloid Aβ deposits and Congo red positive amyloid plaques. A shows detection of amyloid lesions by μMRI, with B showing the corresponding immunohistochemically detected amyloid deposits. This type of approach could be used to make an early definitive diagnosis of AD, as well as allowing for the monitoring of amyloid clearing in vivo.
Supported by Alzheimer Disease Association and NIH grants NS38461, AG15408 and AG17617
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2001 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2001. Online.
Copyright © 2001-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
